Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT06409130 on ClinicalTrials.gov · last registry update 2026-03-12
An unusually large phase 2: 270 participants, more than double the 114 typical for the stage. The sponsor logged completion for 21 November 2025. Primary outcome, as filed: Change in Enhanced Liver Fibrosis (ELF).
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 270
- Started
- 2024-05-20
- Primary completion
- 2025-11-21 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Enhanced Liver Fibrosis (ELF)
Conditions studied
Alcohol-related Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.